Alza Brings Ditropan XL To Abbott As Near-Term Project In $7.3 Bil. Merger
Executive Summary
Abbott would expand its urologic products franchise with the urinary incontinence treatment Ditropan XL as one of the immediate effects of its proposed acquisition of Alza.
You may also be interested in...
Abbott Diagnostics Manufacturing Issues Could Decrease Alza Merger Value
Abbott's pending merger with Alza could give FDA leverage in discussions over quality control problems in Abbott's diagnostics business.
Abbott Diagnostics Manufacturing Issues Could Decrease Alza Merger Value
Abbott's pending merger with Alza could give FDA leverage in discussions over quality control problems in Abbott's diagnostics business.
Abbott To Market Ditropan XL For Five Years: Deal Parallels Alza Merger
Abbott's co-promotion agreements for Ditropan XL with Alza ensure that Abbott will continue to detail the once-daily overactive bladder treatment for the next five years even if the companies do not complete their proposed merger.